Ambit Biosciences today announced that data for the company’s lead compound, AC220, will be presented at the 50 th Annual Meeting of the American Society of Hematology (ASH), occurring December 6 through 9, 2008 in San Francisco. Two oral presentations and one poster presentation will highlight clinical and preclinical data for AC220, a compound that potently and selectively inhibits the ...
More...
More...